Population pharmacokinetic model of PI-88, a heparanase inhibitor

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 743-753

  Hudachek, Susan F ^a   Eckhardt, S Gail ^b   Hicks, Barbara ^c   Gustafson, Daniel L ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c Progen Pharmaceuticals Limited   (Australia)

Author keywords

Heparanase; NONMEM; PI 88; Population pharmacokinetics

Indexed keywords

DOCETAXEL; PI 88; PLACEBO; BETA GLUCURONIDASE; ENZYME INHIBITOR; HEPARANASE; OLIGOSACCHARIDE; PHOSPHOMANNOPENTAOSE SULFATE;

ADULT; ARTICLE; BODY MASS; BODY SURFACE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; AGED; ALGORITHM; AREA UNDER THE CURVE; BIOLOGICAL MODEL; DRUG ANTAGONISM; FEMALE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NEOPLASM; TIME;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; ENZYME INHIBITORS; FEMALE; GLUCURONIDASE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; OLIGOSACCHARIDES; TIME FACTORS; YOUNG ADULT;

EID: 75749146667     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1080-z     Document Type: Article

References (31)

1. SD Baker J Verweij EK Rowinsky RC Donehower JH Schellens LB Grochow A Sparreboom 2002 Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 J Natl Cancer Inst 94 1883 1888 1:CAS:528:DC%2BD3sXlsFyisA%3D%3D 12488482
2. M Basche DL Gustafson SN Holden CL O'Bryant L Gore S Witta MK Schultz M Morrow A Levin BR Creese M Kangas K Roberts T Nguyen K Davis RS Addison JC Moore SG Eckhardt 2006 A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors Clin Cancer Res 12 5471 5480 10.1158/1078-0432.CCR-05-2423 1:CAS:528:DC%2BD28XpvFShsbs%3D 17000682 (Pubitemid 44497263)
3. SA Beshyah V Anyaoku R Niththyananthan P Sharp DG Johnston 1991 The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh Clin Endocrinol (Oxf) 35 409 412 10.1111/j.1365-2265.1991. tb03557.x 1:CAS:528:DyaK38XpvFKisg%3D%3D
4. C Binder 1969 Absorption of injected insulin: a clinical-pharmacological study Acta Pharmacol Toxicol (Copenh) 27 2 1 84
5. PL Bonate S Floret C Bentzen 2004 Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males Br J Clin Pharmacol 58 142 155 10.1111/j.1365-2125.2004.02111.x 15255796 (Pubitemid 39043994)
6. LQ Chow DL Gustafson CL O'Bryant L Gore M Basche SN Holden MC Morrow S Grolnic BR Creese KL Roberts K Davis R Addison SG Eckhardt 2008 A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies Cancer Chemother Pharmacol 63 65 74 10.1007/s00280-008- 0712-z 1:CAS:528:DC%2BD1cXhtF2kur7J 18320191
7. JD Crawford ME Terry GM Rourke 1950 Simplification of drug dosage calculation by application of the surface area principle Pediatrics 5 783 790 1:STN:280:DyaG3c%2Fis12isw%3D%3D 15417279
8. D Du Bois EF Du Bois 1989 A formula to estimate the approximate surface area if height and weight be known. 1916 Nutrition 5 303 311 1:STN:280:DyaK387pvFyjsw%3D%3D 2520314 discussion 312-3
9. EI Ette PJ Williams YH Kim JR Lane MJ Liu EV Capparelli 2003 Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610 623 1:CAS:528:DC%2BD3sXkslGhsbw%3D 12817524
10. A Felici J Verweij A Sparreboom 2002 Dosing strategies for anticancer drugs: the good, the bad and body-surface area Eur J Cancer 38 1677 1684 10.1016/S0959-8049(02)00151-X 1:CAS:528:DC%2BD38XmtVSmtb4%3D 12175683 (Pubitemid 34886509)
11. V Ferro K Fewings MC Palermo C Li 2001 Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88 Carbohydr Res 332 183 189 10.1016/S0008-6215(01)00061-1 1:CAS:528:DC%2BD3MXjtlSrtL8%3D 11434376 (Pubitemid 32451741)
12. A Frid B Linde 1992 Intraregional differences in the absorption of unmodified insulin from the abdominal wall Diabet Med 9 236 239 10.1111/j.1464-5491.1992.tb01768.x 1:STN:280:DyaK383kvV2lsg%3D%3D 1533580
13. JG Gibson WA Evans 1937 Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in ninety normal humans J Clin Invest 16 317 328 10.1172/JCI100860 1:CAS:528:DyaA1cXltVOksg%3D%3D 16694481
14. LB Grochow C Baraldi D Noe 1990 Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82 323 325 10.1093/jnci/82.4.323 1:STN:280:DyaK3c7jsVSisQ%3D%3D 2299683
15. H Gurney 2002 How to calculate the dose of chemotherapy Br J Cancer 86 1297 1302 10.1038/sj.bjc.6600139 1:CAS:528:DC%2BD38XksVSmtLs%3D 11953888 (Pubitemid 34888183)
16. ZH Israili PG Dayton 2001 Human alpha-1-glycoprotein and its interactions with drugs Drug Metab Rev 33 161 235 10.1081/DMR-100104402 1:CAS:528: DC%2BD3MXmtVGlsrk%3D 11495502 (Pubitemid 32703255)
17. PO Iversen DR Sorensen HB Benestad 2002 Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias Leukemia 16 376 381 10.1038/sj.leu.2402376 1:CAS:528: DC%2BD38XjtVGqu7o%3D 11896541
18. JA Joyce C Freeman N Meyer-Morse CR Parish D Hanahan 2005 A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer Oncogene 24 4037 4051 1:CAS:528:DC%2BD2MXlt1Kmsrk%3D 15806157
19. H Kastrissios MJ Ratain 2001 Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis Cancer Invest 19 57 64 10.1081/CNV-100000075 1:CAS:528: DC%2BD3MXisFyntbg%3D 11291557 (Pubitemid 32233803)
20. T Laursen JO Jorgensen JS Christiansen 1994 Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen Clin Endocrinol (Oxf) 40 373 378 1:STN:280:DyaK2c3ksVSltA%3D%3D
21. HQ Miao H Liu E Navarro P Kussie Z Zhu 2006 Development of heparanase inhibitors for anti-cancer therapy Curr Med Chem 13 2101 2111 10.2174/092986706777935230 1:CAS:528:DC%2BD28XnslOksro%3D 16918340 (Pubitemid 44132602)
22. CR Parish C Freeman KJ Brown DJ Francis WB Cowden 1999 Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity Cancer Res 59 3433 3441 1:CAS:528:DyaK1MXks1OmsLs%3D 10416607
23. JJ Perez-Ruixo V Piotrovskij S Zhang S Hayes P De Porre P Zannikos 2006 Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients Br J Clin Pharmacol 62 81 96 10.1111/j.1365-2125.2006.02615.x 1:CAS:528:DC%2BD28XoslKns7c%3D 16842381
24. MJ Ratain 1998 Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 16 2297 2298 1:STN:280: DyaK1czivFyitA%3D%3D 9667242
25. JA Retzlaff WN Tauxe JM Kiely CF Stroebel 1969 Erythrocyte volume, plasma volume, and lean body mass in adult men and women Blood 33 649 661 1:STN:280:DyaF1M7mt1Ojsg%3D%3D 5779153
26. MA Rosenthal D Rischin G McArthur K Ribbons B Chong J Fareed G Toner MD Green RL Basser 2002 Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia Ann Oncol 13 770 776 10.1093/annonc/mdf117 1:STN:280:DC%2BD38zjtlWqsw%3D%3D 12075747 (Pubitemid 34567385)
27. M Sawyer MJ Ratain 2001 Body surface area as a determinant of pharmacokinetics and drug dosing Invest New Drugs 19 171 177 10.1023/A:1010639201787 1:CAS:528:DC%2BD3MXktF2qurc%3D 11392451 (Pubitemid 32423722)
28. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 503 512 10.1007/BF01060893 1:STN:280:DyaL38%2FnslGruw%3D%3D 7310648
29. H Susstrunk B Morell WH Ziegler ER Froesch 1982 Insulin absorption from the abdomen and the thigh in healthy subjects during rest and exercise: blood glucose, plasma insulin, growth hormone, adrenaline and noradrenaline levels Diabetologia 22 171 174 10.1007/BF00283747 1:STN:280:DyaL387oslKmtA%3D%3D 7042427
30. D Wall S Douglas V Ferro W Cowden C Parish 2001 Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides Thromb Res 103 325 335 10.1016/S0049-3848(01)00314-0 1:CAS:528:DC%2BD3MXmsFWrsbs%3D 11562342 (Pubitemid 32787023)
31. G Yu NS Gunay RJ Linhardt T Toida J Fareed DA Hoppensteadt H Shadid V Ferro C Li K Fewings MC Palermo D Podger 2002 Preparation and anticoagulant activity of the phosphosulfomannan PI-88 Eur J Med Chem 37 783 791 10.1016/S0223-5234(02)01347-8 1:CAS:528:DC%2BD38Xosl2it7s%3D 12446036 (Pubitemid 35350842)